ConductScience.org, home
CD160: CD160 molecule
API referenceFor AI assistants

Gene · 11126

Papers2,063

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

1 to 20 of 2,063

Download this page as JSON
TitleJournalYearPMIDFound bySource
Mutant HVEM in lymphoma disrupts BTLA and CD160 regulation of anti-tumor signaling.Front Immunol202642798506PubTator, text miningPubMed
Pre-treatment T-cell Transcriptional Signatures Predict Immunotherapy Outcomes in Melanoma.Res Sq202642687902PubTator, text miningPubMed
Proteomic Insights Into Human Induced Regulatory T Cells: The Role of LPXN and CD160 in Immune Suppression.Mol Cell Proteomics202642624209PubTator, text miningPubMed
Immune dysregulation and exhaustion in EBV- associated hemophagocytic lymphohistiocytosis: insights from single-cell transcriptomics and TCR repertoire analysis.Front Immunol202642620862PubTator, text miningPubMed
Ovarian Cancer-Associated Ascites Accumulates NK Lymphocytes Displaying a Transcriptomic Profile Consistent With the Immature/Secretory CD56bright Subtype.Immunol Cell Biol202642619603PubTator, text miningPubMed
Anti-4CB1: A Novel Selective HVEM-Blocking Antibody Enhancing T-Cell and Macrophage Immunity Against Solid Tumors.Mol Cancer Ther202642617197PubTator, text miningPubMed
CD244 overexpression indicates NK cell dysfunction and tumor progression in diffuse large B-cell lymphoma.Front Immunol202642483169PubTator, text miningPubMed
KIF7 promotes the proliferation of clear cell renal cell carcinoma by activating the WNT/β-catenin signaling pathway.Clin Exp Med202642366250PubTator, text miningPubMed
An exploratory integrative analysis of plasma transcriptomic and proteomic predictors of response to total neoadjuvant therapy in locally advanced rectal cancer.Front Oncol202642339115PubTator, text miningPubMed
Polymorphisms in immune checkpoint genes might influence bladder cancer risk and clinical outcome.Hum Immunol202642284619PubTator, text miningPubMed
dNK3 cells in normal pregnancy and recurrent pregnancy loss: from molecular identity to functional imbalance.Front Immunol202642212143PubTator, text miningPubMed
Triple-Negative Breast Cancer: Molecular Subtypes; Immune Escape; Limitations of Current Immunotherapy; and the BTLA/HVEM/CD160 Axis as an Emerging Target.Curr Issues Mol Biol202642193138PubTator, text miningPubMed
Multiple sclerosis-associated HLA demarcates EBV-specific CD8+ T cells with an exhausted and brain residency phenotype.iScience202642111195PubTator, text miningPubMed
Multi-omics analysis of the gut microbiome and carotid artery atherosclerosis in men with and without HIV.EBioMedicine202642085931PubTator, text miningPubMed
Increased CD95+ or CD160+ double-negative T-cell subsets are associated with incomplete immune reconstitution in ART-treated people living with HIV.Front Immunol202642079587PubTator, text miningPubMed
Genetic variants of CD160, MERTK, and IL15 in natural killer cell-related pathway predict gastric cancer survival.Front Immunol202642064062PubTator, text miningPubMed
Revealing an enhanced cytotoxic immune microenvironment at the human maternal-fetal interface in preeclampsia.Cell Biol Toxicol202641991681PubTator, text miningPubMed
Tumor Core-Edge Divergence in T-Cell Exhaustion and Clonal Expansion in HPV-Related Cervical Squamous Cell Carcinoma Unveiled by Simultaneous Single-Cell RNA and TCR Sequencing.J Med Virol202641964419PubTator, text miningPubMed
Pulmonary microbiota, local inflammation, and tumor progression impact immune checkpoint gene profiles in the lung microenvironment.Physiol Genomics202641921040PubTator, text miningPubMed
Targeted immune response gene expression profiles linked with necrosis and mortality in preterm infants with surgical necrotizing enterocolitis.World J Pediatr Surg202641919181PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Next page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/11126/papers

API referenceFor AI assistants